Astroglial activation of extracellular-regulated kinase in early stages of Alzheimer disease

Journal of Neuropathology and Experimental Neurology

Volumn 65, Issue 2, 2006, Pages 142-151

  Webster, Brian ^a   Hansen, Lawrence ^a,b   Adame, Anthony ^a   Crews, Leslie ^a   Torrance, Magdalena ^a   Thal, Leon ^a   Masliah, Eliezer ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Amyloid ; Astrogliosis; Dementia; Extracellular signal regulated kinase; GFAP; Mini Mental Status Examination; Preclinical Alzheimer disease

Indexed keywords

MITOGEN ACTIVATED PROTEIN KINASE; TAU PROTEIN; BIOLOGICAL MARKER;

AGED; ALZHEIMER DISEASE; ARTICLE; ASTROCYTE; ASTROCYTOSIS; BRAAK STAGE; CELL ACTIVATION; CLINICAL ARTICLE; CLINICAL DEMENTIA RATING; COGNITION; CONTROLLED STUDY; FEMALE; FRONTAL CORTEX; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOREACTIVITY; MALE; MINI MENTAL STATE EXAMINATION; NEURITE; NEUROPATHOLOGY; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RATING SCALE; WESTERN BLOTTING; WHITE MATTER; DISEASE COURSE; ENZYME ACTIVATION; ENZYMOLOGY; METABOLISM; PATHOLOGY; PHYSIOLOGY; REGRESSION ANALYSIS; SIGNAL TRANSDUCTION;

AGED; AGED, 80 AND OVER; ALZHEIMER DISEASE; ASTROCYTES; BIOLOGICAL MARKERS; DISEASE PROGRESSION; ENZYME ACTIVATION; EXTRACELLULAR SIGNAL-REGULATED MAP KINASES; FEMALE; HUMANS; MALE; MAP KINASE SIGNALING SYSTEM; REGRESSION ANALYSIS;

EID: 33645035310     PISSN: 00223069     EISSN: None     Source Type: Journal    
DOI: 10.1097/01.jnen.0000199599.63204.6f     Document Type: Article

References (55)

1. Grundman M, Petersen RC, Ferris SH, et al. Mild cognitive impairment can be distinguished from Alzheimer disease and normal aging for clinical trials. Arch Neurol 2004;61:59-66
2. Haroutunian V, Purohit DP, Perl DP, et al. Neurofibrillary tangles in nondemented elderly subjects and mild Alzheimer disease. Arch Neurol 1999;56:713-18
3. Welsh KA, Butters N, Hughes JP, et al. Detection and staging of dementia in Alzheimer's disease. Use of the neuropsychological measures developed for the Consortium to Establish a Registry for Alzheimer's Disease. Arch Neurol 1992;49:448-52
4. Hwang TJ, Masterman DL, Ortiz F, et al. Mild cognitive impairment is associated with characteristic neuropsychiatric symptoms. Alzheimer Dis Assoc Disord 2004;18:17-21
5. Visser PJ, Verhey FR, Ponds RW, et al. Diagnosis of preclinical Alzheimer's disease in a clinical setting. Int Psychogeriatr 2001;13:411-23
6. Bozoki A, Giordani B, Heidebrink JL, et al. Mild cognitive impairments predict dementia in nondemented elderly patients with memory loss. Arch Neurol 2001;58:411-16
7. Killiany RJ, Hyman BT, Gomez-Isla T, et al. MRI measures of entorhinal cortex vs hippocampus in preclinical AD. Neurology 2002;58:1188-96
8. Masliah E, Mallory M, Hansen L, et al. Synaptic and neuritic alterations during the progression of Alzheimer's disease. Neurosci Lett 1994;174:67-72
9. Masliah E, Mallory M, Alford M, et al. Altered expression of synaptic proteins occurs early during progression of Alzheimer's disease. Neurology 2001:56:127-29
10. Scheff SW, Price DA. Synaptic pathology in Alzheimer's disease. A review of ultrastructural studies. Neurobiol Aging 2003;24:1029-46
11. Bancher C, Brunner C, Lassmann H, et al. Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res 1989;477:90-99
12. Chapman PF, White GL, Jones MW, et al. Impaired synaptic plasticity and learning in aged amyloid precursor protein transgenic mice. Nat Neurosci 1999;2:271-76
13. Masliah E, Rockenstein E. Genetically altered transgenic models of Alzheimer's disease. J Neural Transm Suppl 2000;59:175-83
14. Zhu X, Sun Z, Lee HG, et al. Distribution, levels, and activation of MEK1 in Alzheimer's disease. J Neurochem 2003;86:136-42
15. Roux PP, Blenis J. ERK and p38 MAPK-activated protein kinases: A family of protein kinases with diverse biological functions. Microbiol Mol Biol Rev 2004;68:320-44
16. Klint P, Kanda S, Kloog Y, et al. Contribution of Src and Ras pathways in FGF-2 induced endothelial cell differentiation. Oncogene 1999;18:3354-64
17. Derkinderen P, Enslen HG, Girault J-A. The ERK/MAP-kinases cascade in the nervous system. Neuroreport 1999;10:R24-23
18. McShea A, Zelasko DA, Gerst JL, et al. Signal transduction abnormalities in Alzheimer's disease: evidence of a pathogenic stimuli. Brain Res 1999;815:237-42
19. Zhu X, Lee HG, Raina AK, et al. The role of mitogen-activated protein kinase pathways in Alzheimer's disease. Neurosignals 2002;11:270-81
20. Ferrer I, Blanco R, Carmona M, et al. Phosphorylated mitogen-activated protein kinase (MAPK/ERK-P), protein kinase of 38 kDa (p38-P), stress-activated protein kinase (SAPK/JNK-P), and calcium/calmodulin-dependent kinase II (CaM kinase II) are differentially expressed in tau deposits in neurons and glial cells in tauopathies. J Neural Transm 2001;108:1397-1415
21. Dineley KT, Westerman M, Bui D, et al. Beta-amyloid activates the mitogen-activated protein kinase cascade via hippocampal alpha7 nicotinic acetylcholine receptors: In vitro and in vivo mechanisms related to Alzheimer's disease. J Neurosci 2001;21:4125-33
22. Roder HM, Eden PA, Ingram VM. Brain protein kinase PK40erk converts TAU into a PHF-like form as found in Alzheimer's disease. Biochem Biophys Res Commun 1993;193:639-47
23. Holzer M, Gartner U, Klinz FJ, et al. Activation of mitogen-activated protein kinase cascade and phosphorylation of cytoskeletal proteins after neurone-specific activation of p21ras. I. Mitogen-activated protein kinase cascade. Neuroscience 2001;105:1031-40
24. Carbonell WS, Mandell JW. Transient neuronal but persistent astroglial activation of ERK/MAP kinase after focal brain injury in mice. J Neurotrauma 2003;20:327-36
25. Wang X, Zhu C, Qiu L, et al. Activation of ERK1/2 after neonatal rat cerebral hypoxia-ischaemia. J Neurochem 2003;86:351-62
26. Otani N, Nawashiro H, Yano A, et al. Characteristic phosphorylation of the extracellular signal-regulated kinase pathway after kainate-induced seizures in the rat hippocampus. Acta Neurochir Suppl 2003;86:571-73
27. Abe K, Hisatomi R, Misawa M. Amyloid beta peptide specifically promotes phosphorylation and nuclear translocation of the extracellular signal-regulated kinase in cultured rat cortical astrocytes. J Pharmacol Sci 2003;93:272-78
28. Harris FM, Tesseur I, Brecht WJ, et al. Astroglial regulation of apolipoprotein E expression in neuronal cells. Implications for Alzheimer's disease. J Biol Chem 2004;279:3862-68
29. Rascovsky K, Salmon DP, Ho GJ, et al. Cognitive profiles differ in autopsy-confirmed frontotemporal dementia and AD. Neurology 2002;58:1801-8
30. Salmon D, Thal L, Butters N, et al. Longitudinal evaluation of dementia of the Alzheimer type: A comparison of 3 standardized mental status examinations. Neurology 1990;40:1225-30
31. Hansen L, Samuel W. Criteria for Alzheimer disease and the nosology of dementia with Lewy bodies. Neurology 1997;48:126-32
32. Hansen L, Masliah E, Quijada-Fawcett S, et al. Entorhinal neurofibrillary tangles in Alzheimer disease with Lewy bodies. Neurosci Lett 1991;129:269-72
33. Masliah E, Alford M, Adame A, et al. Abeta1-42 promotes cholinergic sprouting in patients with AD and Lewy body variant of AD. Neurology 2003;61:206-11
34. Hashimoto M, Sagara Y, Everall IP, et al. Fibroblast growth factor 1 regulates signaling via the GSK3{beta} pathway: implications for neuroprotection. J Biol Chem 2002;277:32985-91
35. Cummings B, Pike C, Shankle R, et al. Beta-amyloid deposition and other measures of neuropathology predict cognitive status in Alzheimer's disease. Neurobiol Aging 1996;17:921-33
36. Klucken J, McLean PJ, Gomez-Tortosa E, et al. Neuritic alterations and neural system dysfunction in Alzheimer's disease and dementia with Lewy bodies. Neurochem Res 2003;28:1683-91
37. Martin L, Pardo C, Cork L, et al. Synaptic pathology and glial reponses to neuronal injury precede the formation of senile plaques and amyloid deposits in the aging cerebral cortex. Am J Pathol 1994;145:1358-81
38. Neve RL, Boyce FM, McPhie DL, et al. Transgenic mice expressing APP-C100 in the brain. Neurobiol Aging 1996;17:191-203
39. Barber SA, Uhrlaub JL, DeWitt JB, et al. Dysregulation of mitogen-activated protein kinase signaling pathways in simian immunodeficiency virus encephalitis. Am J Pathol 2004;164:355-62
40. Mandell JW, VandenBerg SR. ERK/MAP kinase is chronically activated in human reactive astrocytes. Neuroreport 1999;10:3567-72
41. Tournier C, Pomerance M, Gavaret JM, et al. MAP kinase cascade in astrocytes. Glia 1994;10:81-88
42. Roback JD, Marsh HN, Downen M, et al. BDNF-activated signal transduction in rat cortical glial cells. Eur J Neurosci 1995;7:849-62
43. Mandell JW, Gocan NC, Vandenberg SR. Mechanical trauma induces rapid astroglial activation of ERK/MAP kinase. Evidence for a paracrine signal. Glia 2001;34:283-95
44. Figiel M, Maucher T, Rozyczka J, et al. Regulation of glial glutamate transporter expression by growth factors. Exp Neurol 2003;183:124-35
45. Yoshida K, Toya S. Neurotrophic activity in cytokine-activated astrocytes. Keio J Med 1997;46:55-60
46. Patel AJ, Wickenden C, Jen A, et al. Glial cell derived neurotrophic factors and Alzheimer's disease. Neurodegeneration 1996;5:489-96
47. Hu J, Akama KT, Krafft GA, et al. Amyloid-beta peptide activates cultured astrocytes: Morphological alterations, cytokine induction and nitric oxide release. Brain Res 1998;785:195-206
48. Mrak RE, Griffin WS. Interleukin-1, neuroinflammation, and Alzheimer's disease. Neurobiol Aging 2001;22:903-8
49. Nagele RG, Wegiel J, Venkataraman V, et al. Contribution of glial cells to the development of amyloid plaques in Alzheimer's disease. Neurobiol Aging 2004;25:663-74
50. Schubert P, Ogata T, Marchini C, et al. Glia-related pathomechanisms in Alzheimer's disease: A therapeutic target? Mech Ageing Dev 2001;123:47-57
51. Dickson DW. The pathogenesis of senile plaques. J Neuropathol Exp Neurol 1997;56:321-39
52. Griffin WS, Nicoll JA, Grimaldi LM, et al. The pervasiveness of interleukin-1 in Alzheimer pathogenesis: A role for specific polymorphisms in disease risk. Exp Gerontol 2000;35:481-87
53. Tacconi MT. Neuronal death: Is there a role for astrocytes? Neurochem Res 1998;23:759-65
54. Hirsch EC, Breidert T, Rousselet E, et al. The role of glial reaction and inflammation in Parkinson's disease. Ann N Y Acad Sci 2003;991:214-28
55. Sabri F, Titanji K, De Milito A, et al. Astrocyte activation and apoptosis: Their roles in the neuropathology of HIV infection. Brain Pathol 2003;13:84-89